As important regulators of cell proliferation and survival, BCL3 and IκBζ might emerge as attractive therapeutic targets to dampen excessive NF-κB activity in certain lymphoid cancers, possibly by pharmacologically preventing the interaction between p50 and BCL3 or IκBζ [245]. Here, NFKBIZ is linked to lymphoma.